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Neurobiology of Disease
Amyloid-/Fyn–Induced Synaptic, Network, and Cognitive
Impairments Depend on Tau Levels in Multiple Mouse
Models of Alzheimer’s Disease
Erik D. Roberson,1,2,3 Brian Halabisky,1,2 JongW. Yoo,4,5,6 Jinghua Yao,1 Jeannie Chin,1,2 Fengrong Yan,1 TiffanyWu,1
Patricia Hamto,1Nino Devidze,1 Gui-Qiu Yu,1 Jorge J. Palop,1,2 Jeffrey L. Noebels,4,5,6,7 and Lennart Mucke1,2
1Gladstone Institute of Neurological Disease and 2Department of Neurology, University of California, San Francisco, San Francisco, California 94158,
3Center for Neurodegeneration and Experimental Therapeutics, Departments of Neurology and Neurobiology, University of Alabama at Birmingham,
Birmingham, Alabama 35294, 4Developmental Neurogenetics Laboratory and Departments of 5Neurology, 6Molecular and Human Genetics, and
7Neuroscience, Baylor College of Medicine, Houston, Texas 77030
Alzheimer’s disease (AD), the most common neurodegenerative disorder, is a growing public health problem and still lacks effective
treatments. Recent evidence suggests that microtubule-associated protein tau may mediate amyloid- peptide (A) toxicity by modu-
lating the tyrosine kinase Fyn.We showed previously that tau reduction prevents, and Fyn overexpression exacerbates, cognitive deficits
in human amyloid precursor protein (hAPP) transgenic mice overexpressing A. However, the mechanisms by which A, tau, and Fyn
cooperate inAD-relatedpathogenesis remain tobe fully elucidated.Herewe examined the synaptic andnetwork effects of this pathogenic
triad. Tau reduction prevented cognitive decline induced by synergistic effects of A and Fyn. Tau reduction also prevented synaptic
transmission andplasticity deficits in hAPPmice.Using electroencephalography to examinenetwork effects,we found that tau reduction
prevented spontaneous epileptiform activity inmultiple lines of hAPPmice. Tau reduction also reduced the severity of spontaneous and
chemically induced seizures inmice overexpressing both A and Fyn. To better understand these protective effects, we recorded whole-
cell currents in acute hippocampal slices from hAPP mice with and without tau. hAPP mice with tau had increased spontaneous and
evoked excitatory currents, reduced inhibitory currents, and NMDA receptor dysfunction. Tau reduction increased inhibitory currents
and normalized excitation/inhibition balance and NMDA receptor-mediated currents in hAPP mice. Our results indicate that A, tau,
and Fyn jointly impair synaptic and network function and suggest that disrupting the copathogenic relationship between these factors
could be of therapeutic benefit.
Introduction
Current treatments for Alzheimer’s disease (AD) are only mod-
estly effective and do not appear to alter the underlying disease
progression. For good reasons, the search for better AD therapies
has focused on amyloid- peptides (A), generally thought to
drive AD pathogenesis (Hardy and Selkoe, 2002; Tanzi and Ber-
tram, 2005). However, disappointing outcomes of initial drug
trials targeting A (Gilman et al., 2005; Green et al., 2009) have
broadened interest in other, downstream targets, including the
microtubule-associated protein tau.
Considerable evidence suggests that tau mediates or enables
the pathogenic effects of A (Go¨tz et al., 2001; Lewis et al., 2001;
Oddo et al., 2003; Tanzi and Bertram, 2005; Roberson et al., 2007;
Ittner et al., 2010;Vossel et al., 2010).We showed that reducing or
eliminating tau expression had striking beneficial effects in hu-
man amyloid precursor protein (hAPP) transgenic mice with
high levels of A in the brain (line hAPPJ20), preventing their
learning and memory deficits, other behavioral abnormalities,
and early mortality (Roberson et al., 2007). Similar protective
effects of tau reduction were observed in an independent hAPP
mouse model (line APP23) (Ittner et al., 2010). The mechanisms
of these beneficial effects are unclear.
Fyn tyrosine kinase has also been implicated in A/tau-
dependent neuronal dysfunction (Haass and Mandelkow, 2010;
Ittner et al., 2010). Increasing neuronal expression of Fyn wors-
ens A-dependent cognitive impairments, neuronal abnormali-
ties, and premature mortality in hAPP mice, whereas ablation of
Fyn protects against A toxicity (Lambert et al., 1998; Chin et al.,
2004, 2005). Fyn also modulates glutamatergic signaling path-
ways affected by A (Salter and Kalia, 2004), phosphorylates tau
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at Tyr18 (Lee et al., 2004), and is crucial in tau-dependent A
toxicity at postsynaptic sites (Ittner et al., 2010).
Regulationof synaptic andnetwork function is a potentialmech-
anistic point of convergence for A, tau, and Fyn. The synapse is a
primary target of A (Selkoe, 2002; Palop and Mucke, 2010), and
AD mouse models have abnormal synaptic transmission and plas-
ticity (Chapman et al., 1999; Hsia et al., 1999; Walsh et al., 2002;
Kamenetz et al., 2003).Dysfunction at the circuit andnetwork levels
in these models may relate to neural network dysrhythmias in AD
(Palop and Mucke, 2009). Pathologically elevated A levels cause
aberrant neuronal activity, as demonstrated by electroencephalo-
graphic (EEG) recordings (Palop et al., 2007; Minkeviciene et al.,
2009; Vogt et al., 2009) and in vivo imaging (Busche et al., 2008).
Increasing Fyn levels also reduces seizure thresholds (Cain et al.,
1995;Kojimaet al., 1998).Tau reduction increases resistanceofmice
to pharmacologically induced convulsive seizures without changing
A levels (Roberson et al., 2007; Ittner et al., 2010).
To elucidate the role of the A–tau–Fyn triad in AD-related
neuronal dysfunction, we examined the effects of tau reduction
on EEGs and synaptic function in several lines of mice expressing
hAPP/A in the absence or presence of a transgene that increases
neuronal Fyn levels. Our results support the hypothesis that, to-
gether, A, tau, and Fyn dysregulate synaptic activity, causing
aberrant neuronal synchrony.
Materials andMethods
Animals. hAPPJ9 and hAPPJ20 mice express an hAPPminigene with the
Swedish (K670N, M671L) and Indiana (V717F) mutations under the
control of the PDGF -chain promoter; hAPP and A levels in hAPPJ20
mice are about double those in hAPPJ9 mice (Mucke et al., 2000).
hAPPJ20micewere crossedwith tau-deficientmice (Dawson et al., 2001)
as described (Roberson et al., 2007) to produce offspring with two
(Tau/), one (Tau/), or no (Tau/) functional Tau alleles in the
presence or absence of hAPP. hAPPJ9 mice were crossed with Tau/
mice for two generations to produce hAPPJ9/Tau/ mice. hAPPJ9/
Tau/ mice do not have robust behavioral abnormalities (Chin et al.,
2005) unless challenged with additional AD-related insults, such as re-
duction of the A-degrading enzyme neprilysin (Farris et al., 2007) or
overexpression of the tyrosine kinase Fyn (Chin et al., 2004, 2005). Dou-
bly transgenic hAPPJ9/Fyn mice exhibit prominent AD-related abnor-
malities (Chin et al., 2004, 2005). To examine the role of tau in these
mice, we separately crossed hAPPJ9 mice and mice overexpressing wild-
type murine Fyn (line N8) (Kojima et al., 1997, 1998) onto the Tau/
background and then bred hAPPJ9/Tau/micewith Fyn/Tau/mice.
TASD41 mice express hAPP with the Swedish and London (V717I)
mutations from the Thy1 promoter (Rockenstein et al., 2001). TASD41
mice were bred with the same Fyn transgenic line to produce TASD41/
Fyn/Tau/mice. TASD41mice were also crossed with Tau/mice to
produce TASD41/Tau/mice, which were then bred with Fyn/Tau/
mice to generate TASD41/Fyn/Tau/mice.
SOD1G93Amice fromThe Jackson Laboratory (stock number 004453)
were crossed with Tau/ mice (Dawson et al., 2001). SOD1G93A/
Tau/ offspring were bred with Tau/ mice to produce SOD1G93A/
Tau/, SOD1G93A/Tau/, and SOD1G93A/Tau/ mice. SOD1G93A
mice were weighed regularly, and age at disease onset was defined as the
point at which weight peaked before beginning to decline. Survival cal-
culation was based on the age at whichmice either died spontaneously or
were killed for being unable to right themselves within 30 s after being
placed on their sides.
A second tau-deficient line, in which the tau locus is replaced by green
fluorescent protein (GFP) (Tucker et al., 2001), was crossed with
hAPPJ20 to produce hAPPJ20/Tau/GFP mice, heterozygous for tau.
These mice were crossed with nontransgenic (NTG)/Tau/GFP mice to
produce both hAPPJ20/Tau/ and hAPPJ20/TauGFP/GFP mice.
All lines had been backcrossed to a consistent strain background,
C57BL/6J. Males and females were used for all experiments, and no sex-
dependent effects were identified (data not shown). Animals were
housed in a pathogen-free barrier facility with a 12 h light/dark cycle and
ad libitum access to food and water. All experiments were approved by
the Institutional Animal Care and Use Committees of the University of
California, San Francisco or Baylor College of Medicine.
Water maze. The water maze pool (122 cm diameter) contained
opaque water with a 14 cm, square platform submerged 2 cm below the
surface. For cued training sessions, a black-and-white striped mast was
mounted above the platform. Mice were trained to locate the platform
over six sessions (two per day, 4 h apart), each with two trials (15 min
apart). The platform location was changed for each session. Hidden plat-
form training began 3 d later, consisting of 10 sessions (two per day, 4 h
apart), each with three trials (15 min apart). Platform location remained
constant in hidden platform sessions, and entry points were changed
semirandomly between trials. The day after hidden platform trainingwas
completed, a 60 s probe trial was performed. The platformwas removed,
and the entry point was in the quadrant opposite the original target
quadrant. Performance was monitored with an EthoVision video-
tracking system (Noldus Information Technology).
Elevated plusmaze.The elevated plusmaze consisted of two open arms
and two closed arms equipped with rows of infrared photocells and a
computer interface (Hamilton-Kinder). Mice were placed individually
into the center of the maze and allowed to explore for 10 min. Beam
breakswere quantified to calculate the amount of time spent anddistance
moved in each arm. The apparatus was cleaned with 0.25% bleach be-
tween the testing of each mouse to standardize odors.
Novel object recognition.Mice were transferred to the testing room and
acclimated for at least 1 h before testing. The testing was performed in a
20 40 cmwhite plastic chamber under red light. On days 1 and 2, mice
were habituated to the testing arena for 15 min. On day 3, each mouse
was presented with two identical objects in the same chamber and al-
lowed to explore freely for 10 min. Twenty-four hours after this training
session, mice were placed back into the same arena for the test session,
during which they were presented with an exact replica of one of the
objects used during training along with a novel, unfamiliar object of
different shape and texture. Object locations were kept constant during
training and test sessions for any given mouse, but objects were changed
semirandomly betweenmice. Arenas and objects were cleaned with 70%
ethanol between each mouse. Behavior was recorded with a digital cam-
corder and time spent exploring each object was scored.
Pentylenetetrazole challenge. Pentylenetetrazole (PTZ) (Sigma) dis-
solved in PBSwas used at a concentration of 5mg/ml. A dose of 40mg/kg
was administered intraperitoneally. Eachmouse was placed in a cage and
observed for 20 min after administration, with video recording. An in-
vestigator analyzed the videotapes to quantify the time course and sever-
ity of seizures according to published scales (Racine, 1972; Loscher et al.,
1991). Seizure severity scores were as follows: 0, normal behavior; 1,
immobility; 2, generalized spasm, tremble, or twitch; 3, tail extension; 4,
forelimb clonus; 5, generalized clonic activity; 6, bouncing or running
seizures; 7, full tonic extension; 8, death.
Video-EEG monitoring. For placement of electrodes, mice were anes-
thetized with Avertin, and four pairs of cranial burr holes weremade; the
most anterior were used for reference and ground, and others were po-
sitioned for bilateral recordings over the temporal, parietal, and occipital
cortices. Teflon-coated silver wire electrodes (0.005 inch diameter) were
implanted in the subdural space and connected to a microminiature
connector (Omnetics Connector). All recordings were performed at least
7 d after surgery on mice freely moving in the test cage. Digital EEG
activity with simultaneous video was recorded with Harmonie software,
version 6.1c (Stellate Systems). EEG activity was monitored for a median
of 8 h total permouse in three 2–3 h sessions during a 1 week period. The
number of abnormal epileptiform spikes (sharp positive or negative de-
flectionswith amplitudes exceeding twice the baseline and lasting 25–100
ms) in each hour of recording and the latency to detection and the num-
ber of seizures were scored. The severity of spontaneous seizures in each
mouse was scored on a scale as follows: 0, no seizures; 1, only noncon-
vulsive seizures; 2, mixed convulsive and nonconvulsive seizures; and 3,
all convulsive seizures.
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Immunohistochemistry. Immunohistochemistry was performed on
floating 30-m-thick microtome sections (Palop et al., 2011). Primary
antibodies were rabbit anti-calbindin D-28K (1:30,000; Swant) or rabbit
anti-NPY (1:8000; Immunostar). Labeling was detected with a biotinyl-
ated secondary antibody and the Vectastain Elite avidin–biotin complex
kit (Vector Laboratories). Images were acquired with a digital micro-
scope (Axiocam; Carl Zeiss). Densitometric quantifications were per-
formed with the Bioquant software package (Bioquant Image Analysis).
Hippocampal remodeling was investigated in hAPPJ9/Fynmice that had
undergone PTZ challenge 20 min before being killed. Because PTZ does
not induce changes in calbindin or NPY on this timescale (data not
shown), the remodeling observed is attributable to previous spontaneous
epileptiform activity, not to induced seizures.
Electrophysiology. Four- to 6-month-old mice were anesthetized with
Avertin and decapitated. The brain was quickly removed and placed in
ice-cold slicing solution containing the following (in mM): 2.5 KCl, 1.25
NaPO4, 10 MgSO4, 0.5 CaCl2, 26 NaHCO3, 11 glucose, and 234 sucrose,
pH7.4 (305 mOsm). Horizontal slices were prepared on a Vibratome-
3000 at either 450 m (for field recordings) or 350 m (for whole-cell
patch clamp) in the solution above. Slices were incubated for 30 min in
standard artificial CSF (ACSF) (30°C) containing the following (in mM):
2.5 KCl, 126 NaCl, 10 glucose, 1.25 NaH2PO4, 1MgSO4, 2 CaCl2, and 26
NaHCO3 (290mOsmol; the pHwas7.4 when gassed with a mixture of
95% O2/5% CO2) and then at room temperature for at least another 30
min before recording. No recordings were made from slices 5 h after
dissection. For recording, individual slices were transferred to a sub-
merged chamber in which they were maintained at 30°C and perfused
with ACSF at a rate of 2 ml/min.
Field EPSPs (fEPSPs) were evoked every 20 s with a parallel bipolar
tungsten electrode (FHC) and recordedwith glass electrodes (3M tip
resistance) filled with 1 M NaCl and 25 mM HEPES, pH 7.3. Recordings
were filtered at 2 kHz (3 dB, eight-pole Bessel), digitally sampled at 20
kHz with a Multiclamp 700A amplifier (Molecular Devices), and ac-
quired with a Digidata-1322A digitizer and pClamp 9.2 software. Data
were analyzed offline with pClamp9 software and OriginPro 8.0 (Orig-
inLab). For recordings in area CA1, the stimulating electrode was placed
in the stratum radiatum at the border of CA3 andCA1, and the recording
electrode was placed150 m away in CA1 stratum radiatum. Synaptic
transmission strength in CA1 was assessed by generating input–output
curves for the relationship between peak amplitude of the fiber volley and
the initial slope of the resulting fEPSP. For each slice, the fiber volley
amplitude and initial slope of the fEPSP responses were measured at
stimulus strengths of 25–800A. For dentate gyrus recordings, the stim-
ulating electrode was moved to the medial perforant path (MPP) in the
dorsal blade; the recording electrode was also placed in the MPP 150
m closer to CA3 than the recording electrode. To overcome inhibitory
feedforward and feedback circuits that are activated during induction of
long-term potentiation (LTP) and that normally prevent robust LTP
induction in the dentate, inhibition by GABAA receptors was blocked by
addition of picrotoxin (50 M; Tocris Bioscience) for field recordings
from the dentate. Input–output curves were generated as in CA1. Stim-
ulus strength was then adjusted to30% of themaximal fEPSP response
for recordings that followed. Paired-pulse ratios were determined by
evoking two fEPSPs 50 ms apart and dividing the initial slope of the
second fEPSP by the initial slope of the first (fEPSP2/fEPSP1). After a 15
min stable baseline was established, LTP was induced in the dentate by
theta burst stimulation (10 theta bursts were applied at 15 s intervals;
each theta burst consisted of 10 bursts, at 200ms intervals, of four 100Hz
pulses).
To evaluate epileptiform bursting, we adjusted the stimulus strength
to evoke fEPSPs30%ofmaximal size (150A), stimulated every 20 s
in the stratum radiatum near the CA1/CA3 border, and recorded field
responses 200 m away in stratum pyramidale of area CA1. Epilepti-
form activity was induced by superfusing bicuculline into the bath (10
M).We quantified the strength of discharges by calculating the coastline
burst index (CBI) (Korn et al., 1987), which is a measure of the length of
the outline of the burst waveform. The CBI is the summated distance
between successive data points in a time window containing the entire
burst using the formula,Vi  Vi1	2  ti  ti1	2, where Vi is field
voltage at time point i (ti), and Vi  1 is field voltage at the previous time
point (ti  1). To correct for underlying baseline “noise,” the CBI for an
equal duration of recording in the absence of bursts was subtracted from
the burst CBI. This sensitive measure of burst intensity is useful for
determining the effects of anti-epileptic interventions (Korn et al., 1987;
Tallent and Siggins, 1999).
Whole-cell recordingsweremade from individual granule cells located
within the dentate gyrus, identified under infrared differential interfer-
ence contrast video microscopy with a Carl Zeiss Axioskop 2 FS plus
microscope. Patch pipettes were pulled from borosilicate glass (WPI)
and filled with the following (in mM): 120 Cs-gluconate, 10 HEPES, 0.1
EGTA, 15 CsCl2, 4 MgCl2, 4 Mg-ATP, and 0.3 Na2-GTP, pH 7.25 (ad-
justed with 1 M CsOH; 285–290 mOsm; patch electrode resistance, 3–6

). Electrophysiological data were obtained from granule cells that
had a holding current between100 and 50 pA at60 mV and a mem-
brane input resistance (Rm)100 M. Series resistance was monitored
throughout recordings; if it increased by 15 
 or varied by 15%,
Figure 1. Tau reduction prevents behavioral deficits in hAPPJ9/Fyn mice. A, Morris water
maze. Therewere no differences on the cued platform task. hAPPJ9/Fyn/Tau/mice, but not
hAPPJ9/Fyn/Tau/ mice, were impaired on the hidden platform task (repeated-measures
ANOVA, p 0.005; on post hoc tests, only hAPPJ9/Fyn/Tau/ mice differed from controls;
n 9–10 mice per group; 4.5– 8 months old). B–D, Morris water maze probe trial. Only
hAPPJ9/Fyn/Tau/micewere impaired, showing less time in the target quadrant (B), fewer
platform crossings (C), and a longer latency to the first crossing of the locationwhere the target
platform had been (D). *p  0.05 on post hoc tests. E, Elevated plus maze. hAPPJ9/Fyn/
Tau/mice showed abnormally high time in the open arms, but hAPPJ9/Fyn/Tau/mice
did not (ANOVA, p 0.0001; Tau hAPPJ9/Fyn interaction, p 0.0005; on post hoc tests,
hAPPJ9/Fyn/Tau/ mice differed from other groups, ***p 0.001; n 9–10 mice per
group; 3.5–7 months old).
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recordings were discarded. Voltage-clamp data were acquired with a
Digidata-1322A digitizer and pClamp 9.2 software (Molecular Devices),
low-pass filtered at 6 kHz (3 dB, eight-pole Bessel), and digitally sam-
pled at 10 kHz with a Multiclamp 700A amplifier (Molecular Devices).
EPSCs were recorded at a holding voltage of60 mV, at which there
are no currents through GABAA receptors. IPSCs were isolated by re-
cording at a holding potential of15mV, the reversal potential of AMPA
receptor (AMPAR)- and NMDA receptor (NMDAR)-mediated cur-
rents. To block GIRK (G-protein-coupled inwardly rectifying K chan-
nel) channels activated by GABAB receptor activation, Cs
was included
in the recording pipette. Evoked PSCs were generated by a bipolar glass
stimulating electrode filled with ACSF and placed in the molecular layer
of the dentate gyrus within 100 m of the patched granule cell. Stimulus
pulses were delivered through a stimulus isolation unit (IsoFLEX;
A.M.P.I.). To generate input–output relationships, the minimal stimu-
lus intensity that evoked a synaptic current was first determined for a 40
s stimulus, which was typically 50–100A. Stimulus durationwas then
increased in 20s intervals to vary input strength. Evoked (e) EPSCs that
were80% of the maximal response were used for subsequent analysis.
Spontaneous andminiature currents were analyzed with event detection
software (wDetecta; J. R. Huguenard, Stanford University, Stanford,
CA). The frequencies of spontaneous (s) and miniature (m) EPSCs were
determined from the average frequency of 200 randomly selected se-
quential events for each cell. For amplitude, individual currents without
other currents contaminating the decay phase were isolated. In each cell,
eEPSCs and sEPSCs were first recorded at 60 mV, then eIPSCs and
sIPSCs were recorded at 15 mV. Then, mEPSCs and mIPSCs were
recorded after addition of tetrodotoxin. Calculations involving compar-
isons between various PSC types (e.g., sIPSCmIPSC frequency) were
made for individual cells in which both datasets were obtained.
To determine theNMDAR/AMPAR ratio, EPSCswere evoked in stan-
dard ACSF in the presence of 50M picrotoxin (picrotoxin was not used
for other whole-cell recordings). Stimulus amplitude was adjusted to
produce single-peaked responses with a short constant latency (2–3 ms,
to ensure monosynaptic responses) and average amplitude of 60 pA.
Evoked EPSCs were recorded at80 and35mV, and in some cells, the
complete current–voltage ( I–V) relationship was determined from80
to35mV in 5mV steps. Because steps to35mV can activate voltage-
dependent currents that decay very slowly (t1/2  5 s), EPSCs were
evoked at low frequency (once every 40 s) to minimize their accumula-
tion and the accumulation of slowly decaying NMDAR-mediated cur-
rents. Three to five traces were used to generate a single average trace at
each holding potential for final analysis. Occasional traces were contam-
inated by stimulus-evoked epileptiform events (resulting from disin-
hibition by picrotoxin), preventing the determination of peak
A B
C D
Figure 2. Tau reduction prevents earlymortality in hAPPJ9/Fynmice and TASD41/Fynmice.
A, B, Kaplan–Meier survival plots in NTG, hAPPJ9, Fyn, and hAPPJ9/Fyn mice on the Tau/
(A) or Tau/ (B) background. There was high mortality in hAPPJ9/Fyn/Tau/ mice (log-
rank test vs other Tau/groups, p 0.0001) but not in hAPPJ9/Fyn/Tau/mice (log-rank
test vs hAPPJ9/Fyn/Tau/, p 0.0001). C, D, Kaplan–Meier survival plots in NTG, TASD41,
Fyn, and TASD41/Fyn mice on the Tau/ (C) or Tau/ (D) background. There was high
mortality in TASD41/Fyn/Tau/mice (log-rank test vs other Tau/ groups, p 0.0001),
whereas TASD41/Fyn/Tau/mice had longer survival (log-rank test vs TASD/Fyn/Tau/,
p 0.0001).
A B
Figure 3. Tau reduction does not alter disease onset or survival in a mousemodel of ALS. A,
Age at onset in SOD1 G93A mice, defined as the age at which weight started to decline, was not
affected by tau reduction. B, Survival to end-stage disease was not altered by tau reduction.
A
B
Figure 4. Effect of tau reduction on network excitability and spontaneous epileptiform ac-
tivity in hAPPmice.A, Induced seizure severity wasmonitored after intraperitoneal injection of
40 mg/kg PTZ in NTG, hAPPJ9, Fyn, and hAPPJ9/Fyn mice (Tau effect, p 0.001 by ANOVA;
*p 0.05 vs NTG and #p 0.05 vs corresponding Tau/ group by post hoc testing; n
16–20mice per group; 5–8months old). B, Severity of electrographically detected spontane-
ous seizures was scored (Tau effect, p 0.005 by ANOVA; **p 0.01 by post hoc tests; n
5–6 mice in each group, median 8 h of EEG; 8–10 months old).
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monosynaptically evoked currents; these traces
were not included in the final average trace
used for analysis. The peak current at80mV,
considered to be fully mediated by AMPAR at-
tributable to magnesium block of NMDAR,
was used to establish AMPAR-mediated re-
sponses. The time for AMPAR currents to decay
fully tobaselinewasdetermined fromthe record-
ings at 80 mV, and a time window after that
point was selected for measurement of the
NMDAR current in recordings at35mV. This
current was designated as theNMDARmeasure-
ment, and INMDA at 35mV/IAMPA at 80 mV was
taken as the NMDAR/AMPAR ratio.
Data analysis. Investigators acquiring and
scoring data were blinded to the genotype and
treatment of mice. Data were analyzed with
GraphPad Prism and SPSS 16.0. Unless speci-
fied otherwise in figure legends, statistical
comparisons were made with the log-rank test
for survival data, the exact test for categorical
data, Kolmogorov–Smirnoff test for compari-
son of cumulative probability plots, and
ANOVA with Bonferroni’s post hoc tests for
other data. A p value 0.05 was considered
significant. Bar graphs show mean SEM.
Results
Tau reduction prevents behavioral
abnormalities and early mortality
caused by synergistic effects of A
and Fyn
We used the Morris water maze to assess
the effect of tau reduction on spatial learn-
ing and memory deficits in hAPPJ9/Fyn
mice, which express approximately half as
much hAPP and A in the brain as
hAPPJ20mice but are sensitized to patho-
genic A effects by neuronal overexpres-
sion of Fyn (Chin et al., 2004, 2005).
ComparedwithTau/ andTau/mice
lacking hAPP and Fyn transgenes (NTG/
Tau/ and NTG/Tau/), hAPPJ9/Fyn/Tau/mice showed a
mild but significant delay in learning the spatial (hidden platform)
component of thewatermaze (Fig. 1A). hAPPJ9/Fyn/Tau/mice,
however, performed significantly better than hAPPJ9/Fyn/Tau/
mice (Fig. 1A). Thebenefits of tau reductionweremoreobvious in a
probe trial conducted 24 h after completion of hidden platform
training. Only hAPPJ9/Fyn/Tau/ mice were impaired, showing
lower percentage dwell time in the target quadrant, fewer platform
crossings, and a longer latency to the first crossing of the area where
the platform had been located (Fig. 1B–D).
hAPPJ9/Fyn/Tau/mice also spentmore time exploring the
open arms of an elevated plusmaze thanNTGwild-type controls
(Fig. 1E), consistent with previous results (Chin et al., 2005). In
contrast, hAPPJ9/Fyn/Tau/mice showed no abnormalities in
this test (Fig. 1E).
Like other hAPP transgenic lines, hAPPJ9/Fyn/Tau/ mice
exhibit early mortality (Chin et al., 2004). We investigated
whether tau reduction improved their survival. Approximately
half of the hAPPJ9/Fyn/Tau/mice died before 8months of age
(Fig. 2A). No early mortality was seen in hAPPJ9/Fyn/Tau/
mice (Fig. 2B).
We observed similar effects in a different hAPP line, TASD41,
crossed with Fyn transgenic mice. Consistent with the higher A
levels and greater impairment of TASD41 mice than of hAPPJ9
mice, TASD41/Fyn/Tau/ mice showed even earlier mortality
than hAPPJ9/Fyn/Tau/mice; none survived longer than2.5
months (Fig. 2C), which precluded analysis of behavioral deficits
at later ages. A beneficial effect of tau reductionwas apparent also
in this line, as evidenced by significantly longer survival in
TASD41/Fyn/Tau/ mice than in TASD41/Fyn/Tau/ mice
(Fig. 2D).
Thus, tau reduction prevents cognitive deficits and earlymor-
tality not only in hAPP singly transgenic mice (Roberson et al.,
2007; Ittner et al., 2010) but also in hAPP mice that have been
sensitized to A-induced deficits through the overexpression
of Fyn.
Tau reduction does not prevent early mortality in a mouse
model of amyotrophic lateral sclerosis
Having observed protective effects of tau reduction in several
AD-related models, and also after systemic kainate administra-
tion (Roberson et al., 2007), we wondered whether tau reduction
is generally neuroprotective or targets a specific pathophysiolog-
ical aspect shared by these models. To address this issue, we in-
vestigated the effects of tau reduction in a mouse model of
amyotrophic lateral sclerosis (ALS). SOD1G93A mice, which ex-
press the human SOD1 gene containing a familial ALS mutation
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Figure 5. Tau reduction prevents hippocampal remodeling in hAPPJ9/Fynmice. A,B, Calbindin levels in themolecular layer of
the dentate gyruswere determinedby immunohistochemistry (representative examples inA) and quantified by densitometry (B).
Levels were significantly decreased in hAPPJ9/Fyn mice. This change was prevented by tau reduction (Tau hAPPJ9/Fyn inter-
action, p 0.001; ***p 0.0001 by post hoc testing; n 38–43mice for Tau/ groups and 11–12mice for Tau/ groups;
6–9months old). C–E, NPY levels were determined by immunohistochemistry (representative examples in C). Immunoreactivity
in themolecular layer (D) andmossy fibers (E)was quantified by densitometry. Levelswere not changed in hAPPJ9 or Fynmice but
were significantly increased in hAPPJ9/Fyn mice; the increase was prevented by tau reduction (Tau hAPPJ9/Fyn interaction,
p 0.001; ***p 0.0001 by post hoc testing; n 43–53 mice for Tau/ groups and 18–20 mice for Tau/ groups; 6–9
months old).
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(Gurney et al., 1994), were crossed with Tau/mice to generate
SOD1G93A/Tau/, SOD1G93A/Tau/, and SOD1G93A/Tau/
mice. We examined both time to disease onset and time to death
or terminal disease, because different manipulations influence
these parameters differentially. Tau reduction did not improve
either age at onset or survival to end-stage disease (Fig. 3). We
conclude that tau reduction is not universally neuroprotective
and hypothesize that it impinges on a mechanism shared by A-
and kainate-induced neuronal dysfunction.
Tau reduction reduces network excitability and ameliorates
the seizure phenotype in hAPPJ9/Fyn mice
We next explored the basis of the protective effect of tau reduc-
tion in hAPPJ9/Fyn mice. High levels of A elicit abnormal pat-
terns of neuronal activity (Palop andMucke, 2010), andmultiple
mouse models of AD exhibit epileptic activity and related hip-
pocampal remodeling (Hsiao et al., 1995; LaFerla et al., 1995;
Moechars et al., 1999; Kumar-Singh et al., 2000; Lalonde et al.,
2005; Palop et al., 2007; Minkeviciene et al., 2009). Because tau
reduction increases the resistance ofmice to excitotoxin-induced
seizures (Roberson et al., 2007), we hypothesized that tau reduc-
tion exerts its beneficial effects in hAPPJ9/Fynmice by preventing
aberrant neuronal activity.
We first examined network excitability by measuring suscep-
tibility to PTZ-induced seizures. Consistent with previous find-
ings in CRND8 (Del Vecchio et al., 2004) and hAPPJ20 (Palop et
al., 2007) mice, hAPPJ9/Fyn mice had
more severe seizures at shorter latencies
than NTG mice (Fig. 4A). Tau reduction
prevented increased susceptibility to
PTZ-induced seizures in hAPPJ9/Fyn
mice (Fig. 4A). Singly transgenic hAPPJ9
mice were also more susceptible to PTZ-
induced seizures, an effect also blocked by
tau reduction (Fig. 4A). In fact, tau reduc-
tion reduced susceptibility to PTZ-
induced seizures across all genotypes,
including NTGmice (Fig. 4A) (Roberson
et al., 2007).
We also investigated whether tau re-
duction modulates spontaneous epilepti-
form activity. Monitoring spontaneous
seizures in hAPPJ9/Fyn mice by video-
EEG recording confirmed a protective ef-
fect of tau reduction. Every hAPPJ9/Fyn/
Tau/ mouse we examined had
spontaneous convulsive seizures. Tau re-
duction had a potent anticonvulsant ef-
fect in hAPPJ9/Fynmice, shifting the type
of epileptic activity from convulsive sei-
zures to milder, nonconvulsive seizures
(Fig. 4B).
Cognitive deficits and early mortality
in hAPPJ9/Fyn mice are probably caused
by synergistic actions of A and Fyn, be-
cause singly transgenic hAPPJ9 or Fyn
lines showed nomajor behavioral impair-
ments or earlymortality (Chin et al., 2004,
2005). We also looked for electrographic
seizures in these singly transgenic lines. As
expected, the severity of spontaneous sei-
zures in hAPPJ9 and Fyn mice was much
lower than in hAPPJ9/Fyn mice, and even
these rare and mild events were ameliorated by tau reduction
(Fig. 4B).
We conclude that A and Fyn have synergistic pro-epileptic
effects in hAPPJ9/Fyn mice and that tau reduction reduces the
severity of the epilepsy phenotype in both singly transgenic lines
and hAPPJ9/Fyn mice.
Tau reduction prevents seizure-induced hippocampal
remodeling in hAPPJ9/Fyn mice
Epileptiform activity in hAPP mice induces inhibitory remodel-
ing in the dentate gyrus (Palop et al., 2007; Minkeviciene et al.,
2009), which likely represents adjustments in the hippocampal
“gate” to chronic overexcitation (Heinemann et al., 1992; Loth-
man et al., 1992; Palop et al., 2007). Hallmarks of this remodeling
include reduction of calbindin in dentate granule cells, GABAer-
gic sprouting of NPY-positive axons in the molecular layer of the
dentate gyrus, and ectopic expression of NPY in the mossy fiber
axons of the granule cells. These changes are seen inmanymodels
of chronic overexcitation and can be induced subacutely by sei-
zure activity (Vezzani et al., 1999; Palop et al., 2007). Because tau
reduction reduced network excitability and spontaneous epilep-
tiform activity, we tested whether it also prevented inhibitory
hippocampal remodeling in hAPPJ9/Fyn mice.
Consistent with previous findings (Chin et al., 2005; Palop et
al., 2007), hAPPJ9/Fyn mice had robust loss of calbindin in the
dentate gyrus (Fig. 5A,B) and aberrant expression of NPY in the
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Figure 6. Tau reduction prevents spontaneous epileptiform activity in hAPPJ20mice. A, EEG tracings from hAPPJ20mice with
different levels of tau expression had a high frequency of generalized epileptiform spikes in the presence of normal tau levels but
markedly fewer spikes in the presence of reduced tau levels. L, Left; R, right; T, temporal; P, parietal; O, occipital. Calibration bars:
2 s, 0.6mV.B, Quantification of spontaneous epileptiform spiking inNTGandhAPPJ20micewith different tau levels. Tau reduction
blocked A-induced spiking in a dose-dependent manner (hAPP tau interaction, p 0.001 by ANOVA; ***p 0.001 vs all
other groups by post hoc test; n 20–32 h of EEG from2–4mice for each of NTG groups, 48–77 h from5–10mice for each of the
hAPPJ20 groups; 7–14 months old). C, Kaplan–Meier analysis showing the duration of recording until an electrographic seizure
was captured in hAPPJ20micewith different tau levels. No seizureswere observed in hAPPJ20/Tau/ or hAPPJ20/Tau/mice
(log-rank test, p 0.05).
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dentate molecular layer and mossy fibers
(Fig. 5C–E). Tau reduction prevented
these alterations in hAPPJ9/Fyn mice
(Fig. 5A–E), consistent with the finding
that it reduces the severity of the sei-
zures that likely trigger this hippocam-
pal remodeling.
Tau reduction prevents EEG
abnormalities and seizures in
hAPPJ20 mice
We showed previously that tau reduction
prevents behavioral abnormalities (Rob-
erson et al., 2007) and hippocampal re-
modeling (Palop et al., 2007) in hAPPJ20
mice. Given our EEG findings in hAPPJ9/
Fyn mice, we examined the effects of tau
reduction on ictal and interictal EEG ac-
tivity in hAPPJ20 mice.
We quantified the frequency of epilep-
tiform spikes in freely moving hAPPJ20
mice. Consistent with previous findings
(Palop et al., 2007), hAPPJ20/Tau/
mice had frequent spikes (Fig. 6A,B). Tau
reduction effectively prevented this ab-
normal activity. In hAPPJ20/Tau/
mice, cortical EEGs showed no spiking,
and even in hAPPJ20/Tau/mice, spike
frequency was not significantly higher
than in controls (Fig. 6A,B). Tau reduc-
tion had no effect on EEG activity in NTG
mice lacking hAPP transgenes (Fig. 6B
and data not shown).
Tau reduction had a similar effect on
seizures. hAPPJ20 mice did not exhibit convulsive seizures dur-
ing routine husbandry or behavioral testing. During EEG record-
ings, however, some hAPPJ20/Tau/ mice had electrographic
seizures. These seizures were always nonconvulsive, and the only
behavioral correlate was motor arrest, sometimes accompanied
by a subtle generalizedmyoclonic jerk (data not shown). Record-
ing EEGs for amedian of 8 h, we observed such seizures in 4 of 12
hAPPJ20/Tau/ mice but in 0 of 6 hAPPJ20/Tau/ or 10
hAPPJ20/Tau/mice (exact test, p 0.05). Kaplan–Meier anal-
ysis of the latency to electrographic seizure detection further
demonstrated the protective effect of tau reduction in hAPPJ20
mice (Fig. 6C). These data indicate that tau reduction potently
suppresses A-induced epileptogenesis.
Tau reduction prevents epileptiform bursting in
hippocampal slices
We further explored the anti-epileptic effect of tau reduction in a
hippocampal slicemodel of epileptiform bursting induced by the
GABAA receptor antagonist bicuculline (Gutnick et al., 1982).
We applied bicuculline while recording in area CA1 and quanti-
fied the strength of resulting epileptiform discharges using coast-
line burst analysis, which measures the outline of the burst
waveformand is useful for assessing burst intensity anddetermining
the effects of anti-epileptic interventions (Korn et al., 1987; Tallent
and Siggins, 1999). Bicuculline-induced epileptiform bursts were
larger in slices fromhAPPJ20/Tau/mice than in slices fromNTG/
Tau/ controls (Fig. 7). Tau reduction markedly suppressed epi-
leptiform bursting in slices from both NTG and hAPPJ20 mice,
consistent with the increased resistance of NTG/Tau/ mice and
hAPPJ20/Tau/mice tochemically inducedseizures invivo (Fig.4)
(Roberson et al., 2007).
Tau reduction prevents synaptic impairments in
hAPPJ20 mice
To better understand the cellular basis of this excitoprotective
effect, we assessed the effects of tau reduction on synaptic trans-
mission and plasticity in hAPPJ20 mice. We first examined min-
iature postsynaptic currents by whole-cell recording from
dentate granule cells in the presence of tetrodotoxin. The fre-
quency of mIPSCs onto granule cells was increased in hAPPJ20
mice (Fig. 8A,B), consistent with previous reports and with the
sprouting of inhibitory axons seen histologically (Palop et al.,
2007). In contrast, the frequency of mEPSCs was decreased (Fig.
8C,D), which is also consistent with other reports of the effects of
hAPP/A (Kamenetz et al., 2003; Shankar et al., 2007). There
were no changes in mIPSC or mEPSC amplitude (supplemental
Fig. 1A,B, available at www.jneurosci.org as supplemental mate-
rial). These results suggest an increase in the number of effective
inhibitory synaptic contacts and a decrease in the number of excita-
tory synaptic contacts onto dentate granule cells in hAPPJ20 mice.
Tau reduction prevented both abnormalities (Fig. 8).
To examine how granule cells respond to spontaneous network
activity in hippocampal slices, we also recorded spontaneous
postsynaptic currents in dentate granule cells in the absence of tetro-
dotoxin. sIPSC frequency was reduced in hAPPJ20/Tau/ (Fig.
9A,B). In contrast to NTG controls, the frequency of sIPSCs in
hAPPJ20/Tau/mice was not much greater than the frequency of
mIPSCs (Fig. 9C), suggesting that inhibitory neurons synapsing
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Figure7. Tau reductionprevents epileptiformbursting inacutehippocampal slices fromNTGandhAPPJ20mice. Bicuculline (10
M) was superfused into the bath during recording in area CA1, and resulting epileptiform discharges were quantified by CBI. A,
Representative traces 5min before and 15min after bicuculline. Note that traces after bicuculline are plotted on a longer timescale
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mice had larger epileptiform bursts than slices fromNTG/Tau/mice, and tau reductionmarkedly reduced bursting in both NTG
and hAPPJ20 slices (hAPP tau interaction, p 0.002 by two-way ANOVA; ***p 0.001 vs all other groups; ###p 0.001 vs
Tau/ groups; NTG/Tau/ and hAPPJ20/Tau/ were not significantly different; n  6–8 slices from 3–4 mice per
genotype).
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onto dentate granule cells had little spontaneous, action potential-
driven activity. Thus, whereas inhibitory interneurons in hAPPJ20/
Tau/mice make an increased number of effective synapses onto
granule cells (as reflected by the higher mIPSC frequency), they are
less active than inhibitory interneurons inNTGmice. Thedecreased
activity of inhibitory interneurons in hAPPJ20/Tau/micemay be
causedby reduced excitatorydrive onto these cells, because blocking
excitatory neurotransmission with 2,3-dihydroxy-6-nitro-7-sulfonyl-
benzo[f]quinoxaline (NBQX) and APV reduced sIPSC frequencies
lessmarkedly in hAPPJ20/Tau/mice than inNTGmice (supple-
mental Fig. 2, available at www.jneurosci.org as supplementalmate-
rial). Reduced intrinsic excitability of the inhibitory interneurons
may also contribute. sIPSCs recorded in the presence of NBQX
and APV include both action potential-independent, stochastic
release of vesicles (mIPSCs) and events caused by action potentials
generated spontaneously in inhibitory cells. Although the sum of
these two components was similar in NTG/Tau/ and hAPPJ20/
Tau/mice (supplemental Fig. 2, available atwww.jneurosci.org as
supplemental material), the higher mIPSC frequency in hAPPJ20/
Tau/mice (Fig. 8A) indicates that the sIPSC component attrib-
utable to spontaneous action potentials in inhibitory interneurons
was smaller in hAPPJ20/Tau/mice, suggesting reduced intrinsic
excitability of the inhibitory neurons.
Tau reduction prevented the decrease in sIPSC frequency in
hAPPJ20 mice; in fact, sIPSC frequencies were higher in NTG/
Tau/ and hAPPJ20/Tau/ mice than
in NTG/Tau/ controls (Fig. 9A,B).
Thus, tau reduction may counteract A,
at least in part, by enhancing the activity of
inhibitory interneurons.
hAPPJ20/Tau/ mice showed no al-
terations in the frequency of sEPSCs or in
the amplitudes of either sIPSCs or sEPSCs
(supplemental Fig. 3, available at www.
jneurosci.org as supplemental material).
However, the ratios of sEPSC to sIPSC fre-
quency provided evidence that excitation
and inhibition are imbalanced in dentate
granule cells of hAPPJ20/Tau/mice,
with a shift toward more excitation (Fig.
9D). This change was also blocked by tau
reduction (Fig. 9D). A similar pattern was
observed when we recorded evoked
postsynaptic currents. eIPSC amplitude
was reduced in hAPPJ20/Tau/ slices
(Fig. 9E), whereas eEPSC amplitude was
mildly increased (Fig. 9F). This increase is
likely attributable to the decrease in inhi-
bition (Fig. 9A–C,E), because hAPPJ20/
Tau/ mice showed no increase in
AMPA receptor-mediated postsynaptic
currents or input–output relationships in
the presence of picrotoxin (supplemental
Fig. 2, available at www.jneurosci.org as
supplemental material) (Palop et al.,
2007; Harris et al., 2010). Tau reduction
also blocked the changes in evoked IPSCs
and EPSCs (Fig. 9E,F). We conclude that
tau reduction blocks the excitation/inhi-
bition imbalance induced by hAPP/A in
dentate granule cells.
We also investigated the effects of tau
reduction on abnormalities of synaptic
plasticity in the dentate gyrus. At medial perforant path synapses
onto dentate granule cells, paired-pulse facilitation (PPF) and
LTP are impaired in hAPPJ20 mice (Palop et al., 2007; Sun et al.,
2008; Harris et al., 2010). Tau reduction blocked both of these
abnormalities (Fig. 10A,B), preventing impairment of both
short-term and long-term plasticity. The impairment of LTP in
hAPPJ20 mice is unlikely to be attributable to changes in inhibi-
tion, because GABA receptors were blocked during the record-
ings. Thus, we investigated NMDA receptor function in dentate
granule cells by whole-cell recordings of isolated NMDA- and
AMPA-receptor-mediated currents. The NMDA/AMPA current
ratio was depressed in hAPPJ20/Tau/mice (Fig. 10C) because
of impairments in NMDA receptor-mediated currents (Supple-
mental Fig. 4, available at www.jneurosci.org as supplemental ma-
terial). This effect, too, was blocked by tau reduction (Fig. 10C).
Finally, we examined synaptic physiology in area CA1. PPF
and LTP are unimpaired in area CA1, but synaptic transmission
is decreased in hAPPJ20 mice, as evidenced by altered input–
output relationships (Palop et al., 2007; Sun et al., 2008; Harris et
al., 2010). We reproduced this finding in hAPPJ20/Tau/mice
and found that tau reduction normalized the input–output
curves (Fig. 10D).
Thus, tau reduction prevents a wide range of abnormalities in
synaptic transmission and plasticity in hippocampal subfields of
hAPPJ20 mice.
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Figure 8. Tau reduction prevents abnormalities inminiature postsynaptic potentials in dentate granule cells of hAPPJ20mice.
Whole-cell recordings were made from acute hippocampal slices. A and C show mean frequency; B and D show cumulative
probability plots for interevent intervals. A, B, mIPSC frequency was increased in hAPPJ20 granule cells, and the change was
blocked by tau reduction (***p 0.001 vs NTG/Tau/ by Kolmogorov–Smirnoff test). C, D, mEPSC frequency was reduced in
hAPPJ20 granule cells, and the change was blocked by tau reduction (***p 0.001 vs NTG/Tau/ by Kolmogorov–Smirnoff
test). For both mIPSC and mEPSCs, n 2000–2400 events from 10–12 cells (200 events from each) in 4 mice per genotype.
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Discussion
This study demonstrates that tau reduction suppresses spontane-
ous seizure activity and corrects synaptic deficits in hAPP mice
with high A levels and in hAPP/Fyn mice with lower A levels
that are sensitized to A by coexpression of Fyn. Our data indi-
cate that tau enables synaptic effects implicated in A-induced
neuronal dysfunction, because tau reduction prevented LTP im-
pairment, NMDA receptor dysfunction, and excitation/inhibi-
tion imbalance in hAPP mice. At the network level, singly
transgenic hAPP mice had interictal spikes and nonconvulsive
seizures that were eliminated by tau reduction. Coexpression of
hAPP/A and Fyn caused overt convulsive seizures that were also
ameliorated by tau reduction. Furthermore, tau reduction pre-
vented cognitive impairment and early mortality in mice with
deficits caused by synergistic effects of A and Fyn. Our findings
illuminate the synaptic and network mechanisms underlying co-
pathogenic effects of A, tau, and Fyn. Together with previous
studies showing dual interactions between Fyn and A or be-
tween Fyn and tau (Lambert et al., 1998; Lee et al., 1998;William-
son et al., 2002; Chin et al., 2004, 2005; Ittner et al., 2010), these
findings suggest that the A–Fyn–tau triad contributes to AD-
related cognitive impairments, at least in part, by eliciting aberrant
neural network activity and that disrupting their copathogenic rela-
tionship could be of therapeutic benefit.
Tau reduction is protective in several AD-related models but
not in a model of ALS
The protective effects of tau reduction we identified in hAPPJ9,
hAPPJ9/Fyn, and TASD41/Fyn mice add to a growing body of
evidence that tau reduction protects against the pathogenic ef-
fects of A in vivo. We showed previously that tau reduction
prevented learning and memory deficits and early mortality in
hAPPJ20 mice (Roberson et al., 2007), and similar results were
recently obtained in APP23 mice (Ittner et al., 2010). Tau reduc-
tion also prevented learning and memory impairments in a
mouse overexpressing glycogen synthase kinase 3 (Go´mez de
Barreda et al., 2010), which has been implicated in A-induced
pathogenesis (Hooper et al., 2008; Li et al., 2009).
In contrast, we found no beneficial effect of tau reduction in a
mutant SOD1-transgenic mousemodel of ALS. This selectivity is
interesting, particularly because elimination of neurofilaments
was protective in a related ALS model (Williamson et al., 1998),
indicating that manipulation of different cytoskeletal gene prod-
ucts can block distinct pathogenic pathways. Crossing a mouse
model of Niemann–Pick type C (NPC) disease with tau knock-
out mice actually had adverse effects (Pacheco et al., 2009), further
highlighting that tau reduction is beneficial in specific, AD-related
circumstances. The detrimental effect of tau reduction inNPCmice
is probably not attributable to the use of a different Tau/ line (a
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Figure 9. Tau reduction prevents excitation–inhibition imbalance in dentate granule cells of hAPPJ20 mice. Whole-cell recordings were made from acute hippocampal slices without pharma-
cological receptor blockers. A, B, sIPSC frequency was lower in hAPPJ20 granule cells and higher in Tau/ groups than in NTG/Tau/ controls (***p 0.001 and **p 0.01 vs NTG/Tau/
by Kolmogorov–Smirnoff test; n 2800–3000 events from14–15 cells, 200 events fromeach, in 4mice per genotype). C, Frequency of action potential-driven IPSCs. For each cell fromwhich both
sIPSC andmIPSC frequency datawere obtained,we subtracted the frequency ofmIPSCs (recorded in the presence of TTX; see Fig. 8A) from the frequency of sIPSCs; the difference reflects IPSCs driven
byactionpotentials. hAPPJ20/Tau/ cells hadalmost noactionpotential-driven IPSCs, because the sIPSC frequencywas essentially the sameas themIPSC frequency (hAPP tau interaction,p
0.001by two-wayANOVA; ***p0.001vs all othergroupsbypost hoc test;n10–12cells from4micepergenotype).D, hAPPJ20/Tau/ cells hadan increased ratioof sEPSC to sIPSC frequency,
and this abnormality was prevented by tau reduction (hAPP tau interaction, p 0.05 by two-way ANOVA; ***p 0.001 vs all other groups by post hoc test; n 14–15 cells from 4mice per
genotype). E, Amplitude of IPSCs onto granule cells evoked by stimulation in themolecular layerwas reduced in hAPPJ20/Tau/mice but not in hAPPJ20/Tau/mice (hAPP tau interaction,
p 0.002 by two-way ANOVA; ***p 0.001 vs all other groups by post hoc test; n 10 cells from 4mice per genotype). F, Amplitude of evoked EPSCs onto granule cells was mildly increased in
hAPPJ20/Tau/mice but not in hAPPJ20/Tau/mice (hAPP tau interaction, p 0.14; hAPP effect, p 0.05 by two-way ANOVA; *p 0.05 vs NTG/Tau/ by post hoc test; n 10 cells
from 4mice per genotype).
708 • J. Neurosci., January 12, 2011 • 31(2):700–711 Roberson et al. • Tau Reduction Prevents A/Fyn-mediated Abnormality
GFPknock-in) (Tucker et al., 2001), because that line had beneficial
effects in hAPPJ20 mice (supplemental Fig. 5, available at www.
jneurosci.org as supplemental material) and APP23 mice (Ittner et
al., 2010). Tau ablation was reported recently to change A levels
and plaque loads in opposite directions and to worsen behavioral
deficits in hAPP mice from line Tg2576 at an age when behavioral
deficits in this line tend to be somewhat variable (Dawson et al.,
2010). Because these results are inconsistent with the findings
from hAPPJ20, hAPPJ9, hAPPJ9/FYN, and TASD41/FYN mice
described here and in our previous study (Roberson et al., 2007) as
well as with findings inAPP23mice (Ittner et al., 2010), theymay be
specific to the Tg2576model.
Tau reduction prevents aberrant neuronal activity
Given the differential effects of tau reduction on A-related versus
SOD1- or NPC-related impairments, we hypothesized that tau re-
duction impingesona specific aspectofA-inducedpathogenesis.A
likely candidate is A-induced aberrant excitatory activity, which
has been documented inmultiplemousemodels (Hsiao et al., 1995;
LaFerla et al., 1995;Moechars et al., 1999; Kumar-Singh et al., 2000;
Lalondeet al., 2005;Palopet al., 2007;Minkevicieneet al., 2009;Vogt
et al., 2009). Because tau reduction increases resistance to pharma-
cologically induced seizures (Roberson et al., 2007), we studied its
effects on the epilepsy phenotype in several
AD-related mouse models and in hip-
pocampal slices. Examination of EEG spik-
ing, spontaneous and PTZ-induced
seizures, and compensatory hippocampal
remodeling all confirmed a robust antiepi-
leptic effect of tau reduction. Tau reduction
prevented both the mild seizure phenotype
inhAPPJ9mice and themore severepheno-
type in hAPPJ20 mice. It also reduced the
severity of seizures and prevented compen-
satory remodeling in hAPPJ9/Fyn mice. Fi-
nally, it prevented pharmacologically
induced epileptiform bursting in hip-
pocampal slices from both NTG and
hAPPJ20 mice. Thus, tau has an important
role in regulating neuronal activity and syn-
chrony, and its presence in the brain con-
tributes to seizure susceptibility.
Genetic background is an important fac-
tor to consider in these types of experiments
because different strains vary in susceptibil-
ity to seizures and to hAPP/A-induced
neuronal dysfunction. Interestingly, strains
that are relatively resistant to seizures, such
as 129 strains (McKhann et al., 2003), are
also relatively resistant to hAPP/A-
induced premature mortality and cognitive
impairment (Krezowski et al., 2004),
whereas strains that are relatively suscepti-
ble to seizures, such as FVB/N (Kasugai et
al., 2007), are also more susceptible to
hAPP/A-induced premature mortality
and cognitive impairment (Hsiao et al.,
1995; Carlson et al., 1997). Importantly, we
used a consistent genetic background,
C57BL/6J,whichhas susceptibility interme-
diate between 129 and FVB/N. Because AD
is associated with both prematuremortality
(Walsh et al., 1990; Roberson et al., 2005)
and increased incidenceof seizures (PalopandMucke,2009),mouse
strains that also combine these characteristics when challengedwith
high cerebral A levels may simulate the human condition more
closely than those that do not. However, prematuremortality is not
a universal feature of ADmouse models, and additional research is
needed to clarify the causal relationships between hAPP/A, epilep-
tiform activity, premature mortality, and cognitive deficits, all of
which are ameliorated by tau reduction.
Synaptic effects of tau reduction
Our synaptic physiology data indicate that tau reduction corrects
several abnormalities in multiple hippocampal subregions of
hAPPJ20 mice. In the dentate gyrus, tau reduction corrected the
increasedmIPSC frequency and decreasedmEPSC frequency, exci-
tation/inhibition imbalance (decreased spontaneous/evoked inhib-
itory responses and increased spontaneous/evoked excitatory
responses), NMDA receptor dysfunction, and deficits in PPF and
LTP. In area CA1, tau reduction corrected the decline in evoked
excitatory field potentials and blocked pharmacologically induced
epileptiform bursting. Future experiments will need to determine
which of these abnormalities reflect primary effects ofA andwhich
are secondary, compensatory changes in the circuit.
BA
DC
Figure10. Taureductionpreventsabnormalities insynaptic transmissionandplasticity inhAPPJ20mice.Field (A,B,D)andwhole-cell
(C) recordingsweremade fromacute hippocampal slices.A, Paired-pulse ratio in themedial perforant pathwaywas reduced in hAPPJ20/
Tau/mice but normal in hAPPJ20/Tau/mice (hAPP tau interaction, p 0.01 by two-way ANOVA; **p 0.01 vs all other
groups by post hoc tests;n 8 slices from3–4mice per genotype.)B, Theta burst stimulation-induced LTP at themedial perforant path
synapsewas impaired in hAPPJ20/Tau/mice, and this deficitwas blocked by tau reduction (repeated-measures ANOVAondata from
minutes 51–60, p 0.01; n 10–12 slices from 3–4 mice per genotype). C, Evoked NMDA and AMPA currents were recorded by
whole-cell patch clamp on dentate granule cells. NMDA/AMPA ratios were depressed in hAPPJ20/Tau/ mice, and this deficit was
blockedbytaureduction(hAPP tau interaction,p0.001bytwo-wayANOVA;***p0.001vsallothergroupsbyposthoc tests;n
15–18cells from4micepergenotype).D, Synaptic strength inareaCA1was significantlydecreased inhAPPJ20/Tau/mice (repeated-
measures ANOVA, p 0.01) but normal in hAPPJ20/Tau/mice (n 10–12 slices from3–4mice per genotype).
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NTG/Tau/ mice are protected from epileptogenic agents
other than A, such as PTZ and kainic acid (Roberson et al., 2007).
We saw a similar effect electrophysiologically, withmuch less burst-
ing after GABA receptor blockade in NTG/Tau/ slices than in
NTG/Tau/ slices. NTG/Tau/mice also had a higher sIPSC fre-
quency than NTG/Tau/ mice, which might contribute signifi-
cantly to the protective effect of tau reduction. Inhibitory
interneuronsmay be an important target of A (Busche et al., 2008;
Palop and Mucke, 2010), and it will be important to examine the
effects of tau reduction on GABAergic transmission inmore detail.
Mechanisms and implications
The findings presented here indicate that tau mediates the effects
of A and Fyn at both the synaptic and network levels. A variety
of mechanisms have been proposed to explain how tau reduction
might prevent A toxicity, ranging from alteredmicrotubule sta-
bility (Rapoport et al., 2002; Liu et al., 2004; King et al., 2006),
elimination of a toxic tau fragment (Park and Ferreira, 2005),
regulation of neuronal activity (Roberson et al., 2007), and
changes in subcellular localization of Fyn (Ittner et al., 2010). In
addition, although Tau/mice do not exhibit abnormal axonal
transport in the absence of exogenous A (Yuan et al., 2008), tau
is required for A to disrupt axonal transport in primary neurons
(Vossel et al., 2010). These mechanisms are not mutually exclu-
sive, and additional studies are needed to assess their relative
importance and potential interdependence. Another important
objective is to determine whether the protective effects of tau
reduction against A-induced aberrant neuronal activity and
cognitive deficits depend on removal of a toxic tau species or
reduction of a normal tau function that permits A to elicit neu-
ronal dysfunction.
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